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Definition
Bronchiolitis is a viral-induced lower respi-
ratory tract infection (LRTI) that occurs 
predominantly in children <2 years of age, 
particularly infants.[1] 
Causative organisms
The most frequent cause of severe bronchio-
litis is respiratory syncytial virus (RSV) 
infection, with other respiratory viruses 
(para-influenza virus (PIV), influenza virus, 
human metapneumovirus (hMPV) and 
measles virus) being less common or for 
which definitive attribution is yet to be 
established (e.g. rhinovirus (RV), bocavirus 
and coronavirus) (Table 1).
Epidemiology
Epidemiological studies on bronchiolitis 
often include all children presenting with 
physician-diagnosed LRTI, and may overesti-
mate the true incidence of bronchiolitis alone. 
In a prospective, hospital-based surveillance 
study of 8 723 child ren under-5 with physi-
cian-diagnosed LRTI, from five sites in four 
provinces in South Africa (SA), from 2009 
to 2012 (severe acute respiratory illness 
(SARI) programme), the overall prevalence 
of respiratory viruses was 78%. The viruses 
that were isolated included RV in 37%, RSV 
in 26%, adenovirus in 26%, influenza virus 
in 7% and hMPV in 5%.[2] In 2009 and 2010, 
this surveillance study evalua ted respiratory 
viruses by a 10-plex real-time reverse-trans-
cription polymerase chain reaction (rRT-
PCR).[3] Respiratory viral co-infections among 
cases enrolled indicated 39.6% with single 
viral infections, while 17.4% had ≥2 viral 
co-infections.[3] 
RV
Many studies show RV to be associated with 
bronchiolitis; however, the high prevalence 
of RV in healthy asymptomatic children 
limits definitive attribution of its role in the 
pathogenesis of bronchio litis. Early studies 
have suggested that oxygen saturation is 
generally not as low in children with RV- 
associated bronchiolitis as in those with 
RSV-associated bronchio litis.[4] However, 
more recent studies suggest that RV may be 
more sinister.[5] All three types of RV have 
been identified in SA, although RV-A and 
RV-C are more common than RV-B. RV 
is associated with symptomatic respiratory 
illness; however, there is no association 
between RV type and disease severity.[6] 
RV-D has subsequently been identified.[7] 
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Table 1. Respiratory viruses associated 
with bronchiolitis
Respiratory syncytial virus
Rhinovirus
Adenovirus
Para-influenza virus (especially type 3)
Influenza virus
Human metapneumovirus
Bocavirus
Coronavirus
Measles virus
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RSV
The two major RSV subgroups are A (RSV-A) and B (RSV-B), which 
are further characterised into several genotypes, based on antigenic 
and genetic variability of the second hypervariable region of the 
G-protein. Several genotypes can co-circulate in a single epidemic 
season, and different genotypes can dominate in consecutive seasons. 
Over a 15-year study period in SA, RSV-A and RSV-B genotypes 
evolved, resulting in replacement of all genotypes over the study 
period.[8] Whereas genotype A virus, rather than RSV-B, has more 
frequently been associated with more severe disease, other studies 
have occasionally reported more severe disease with RSV-B than 
RSV-A. These differences could be related to the extent of community 
immunity to the specific genotype, with more severe disease 
observed in the presence of lower community immunity to that 
strain. 
RSV is the most common cause of moderate or severe bronchiolitis 
and a leading cause of LRTI among young children. RSV-associated 
bronchiolitis occurs most frequently in infancy, being 2 - 3 times 
higher than in children >5 years. Infection with RSV does not result 
in permanent or long-term immunity, as re-infections, albeit of lesser 
severity, are common and may be experienced throughout life.[9] An 
estimated 33.8 million new episodes of RSV-associated acute lower 
respiratory tract infection (ALRTI) occurred worldwide in 2005 in 
children under-5 (22% of episodes), with at least 3.4 (2.8 - 4.3) million 
episodes necessitating hospital admission. An estimated 66 000 - 
199 000 children under-5 died from RSV-associated ALRTI in 2005, 
with 99% of these deaths occurring in developing countries.[10] 
In the SARI surveillance programme, the prevalence of RSV 
among 4 293 LRTI hospitalisations in under-5 children was 27%, 
including 863 of 1 157 (75%) <12 months of age, of whom 637 (74%) 
were <6 months old. Nine of 1 153 children with RSV-associated 
ALRTI died (case fatality proportion 1%), which was lower than 
the 2% (74 of 3 122) of children in whom RSV was not identified 
(p<0.001). Children admitted with RSV-associated ALRTI were 
younger than those who tested RSV negative (adjusted odds ratio 
(AOR) 2.8; 95% confidence interval (CI) 2.1 - 3.7 for age <6 months 
v. 23 - 59 months). Also, patients with RSV-associated ALRTI were 
more likely to present with cough (AOR 9.0; 95% CI 5.5 - 14.9) and 
lower-chest retractions (AOR 1.4; 95% CI 1.2 - 1.7) than children with 
non-RSV-associated ALRTI.[11]
The incidence of RSV-associated severe ALRTI in children from 
developing and developed countries (5.5/1 000 v. 5.6/1 000) is equal, but 
the case fatality rate is higher in the former (2.1% v. 0.3 - 0.7%).[10] The 
case fatality rate for individual risk factors for RSV-associated disease 
among children with chronic lung disease is 3.5 - 23.0%, congenital 
heart defects (CHDs) 2 - 37%, nosocomial infection 0 - 12.2%, intensive 
care unit admission 1.1 - 8.8%, and prematurity 0.6 - 1.0%.[12] The risk 
of mortality with RSV disease increases threefold among haemodyna-
mically significant (complex disease with pulmonary hypertension) 
CHDs.[13] HIV is associated with a 2 - 3-fold greater risk of RSV 
disease and also with higher case fatality proportions (12% v. 2% in 
HIV-uninfected children).[11]
Bacterial-viral interactions 
Whereas bronchiolitis is exclusively due to respiratory viral 
infections, with little evidence of bacterial co-infection,[14] the 
former could nevertheless predispose to superimposed bacterial 
infections.[15] These complicated cases of respiratory viral infections 
present with the more classic signs of pneumonia, including 
alveolar consolidation on chest radiographs, raised C-reactive 
protein (≥40 mg/dL), temperature ≥38°C, crepitations and bron-
chial breathing on chest auscultation. The role of bacterial co- 
infections in children with a respiratory virus-associated pneumonia 
is frequently underemphasised owing to limited tools for diagnosing 
bacterial pneumonia, with blood culture sensitivity ranging from 
3% to 18% for detecting pneumococcal pneumonia.[16] However, 
epidemiological studies have identified a strong temporal association 
between some respiratory viruses and invasive pneumococcal disease. 
Included among these are studies on the temporal association of the 
influenza virus and RSV epidemics and invasive pneumococcal 
disease.[17] 
Further evidence for this association was observed in an SA 
randomised controlled trial of an investigational 9-valent pneumo-
coccal conjugate vaccine (PCV), in which children vaccinated with 
PCV had a 32% lower risk of being hospitalised for a viral-associated 
pneumonia compared with placebo recipients.[18] This lower risk of 
respiratory virus-associated hospitalisation was evident for influ-
enza virus, hMPV and RSV-associated pneumonia.[19] The biological 
rationale for the reduction in respiratory virus-associated pneumonia 
among the PCV-vaccinated children in this study, was attributed to 
vaccination having prevented the superimposed vaccine-serotype 
pneumococcal co-infection, which would have led to progression 
to more severe disease – culminating in hospitalisation among the 
placebo recipients. Notably, there was no reduction in hospitalisation 
for bronchiolitis among the PCV9 vaccinated children, corroborating 
that pneumococcal co-infection was unlikely to have played a role in 
the pathogenesis of bronchiolitis. 
The pathogenesis of increased susceptibility to pneumococcal 
infection following RSV infection in mice-model studies has been attri-
buted to RSV G glycoprotein-binding penicillin-binding protein 1a 
increasing pneumococcal virulence owing to up-regulation of viru-
lence genes, pneumococcal toxin and pneumolysin. This could lead 
to an increase in the inflammatory response and bacterial adherence 
to human ciliated epithelial cultures.[20,21] This again is corroborated 
by studies in children with alveolar pneumonia associated with RSV 
or RV infection, among whom higher pneumococcal bacterial load 
was observed in the nasopharynx than in children with RSV or RV 
in the absence of alveolar consolidation.[22] Observations from the 
SA study were recently corroborated by an ecological study in the 
USA, in which RSV and pneumococcal pneumonia were shown to 
share a distinctive spatiotemporal pattern, with RSV associated with 
a significant increase in the incidence of pneumococcal pneumonia 
in children <1 year of age (attributable percent (AP) 20.3%; 95% 
CI 17.4 - 25.1%) and among children aged 1 - 2 years (AP 10.1%; 95% 
CI 7.6 - 13.9%). Similarly, influenza was associated with an increase in 
pneumococcal pneumonia among children aged 1 - 2 years (AP 3.2%; 
95% CI 1.7 - 4.7%). After the introduction of PCV7 into the USA 
immunisation programme examining physician-coded diagnosis, 
the authors observed a decline in RSV-coded hospitalisations for 
children <1 year old (AP −18.0%; 95% CI −22.6 to −13.1% for 
2004/2005 - 2008/2009 v. 1997/1998 - 1999/2000).[23] 
Although the abovementioned data support an interaction between 
RSV and pneumococcal superimposed infections, these specifically 
refer to children who are hospitalised with RSV-associated pneu-
monia and not to those with bronchiolitis or milder outpatient 
RSV-associated illness. As such, empiric antibiotic treatment against 
pneumococcus with RSV-associated pneumonia is only warranted in 
a child who is hospitalised and whose clinical syndrome is more in 
keeping with pneumonia than uncomplicated bronchiolitis. 
Seasonality
There are several factors responsible for an outbreak of RSV infection. 
These include geographical locations (latitude and altitude) and 
climatic factors (temperature, barometric pressure, relative humidity, 
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vapour tension, hours of light, precipitation, dewpoint). In most 
temperate regions, such as the USA and Europe, RSV outbreaks last 
an average of 3 - 4 months, with a peak incidence during winter, 
although the exact timing of onset of the outbreak is uncertain. In 
tropical regions, RSV outbreaks are not distinctly related to season, 
but often occur during the hottest rainy season. In SA, the peak in 
RSV season varies slightly by province, with onset of the epidemic 
usually in KwaZulu-Natal in December - January, in Gauteng in 
February - March, and followed by the Western Cape in March.[24] 
In 2009 and 2010, the SARI programme reported seasonality for RSV, 
influenza A and B viruses, enterovirus, hMPV, and PIV type 3. RSV 
circulation was evident from February to June, before the influenza season, 
which occurred from May to September. Peak activity for hMPV was 
observed between July and August and for PIV type 3 between September 
and November. Adenovirus and RV were identified perennially without 
any obvious peaks, while PIV types 1 and 2 were detected sporadically 
throughout the 2 years.[3]
The important implication of these new seasonality findings is 
that where prophylaxis is possible, as in the case of RSV, it should be 
commenced in January of each year.
RSV in HIV-infected children
RSV may be identified throughout the year in HIV-infected child ren 
because of prolonged shedding of the virus (up to 100 days post infection) 
compared with 5 - 7 days in HIV-uninfected children.[25] Although HIV-
infected children with RSV-associated ALRTI are at increased risk of 
hospitalisation and death, this could be due to greater susceptibility to 
Pneumocystis jirovecii pneumonia and other co-infections. The increased 
risk of RSV-associated ALRTI hospitalisation in HIV-infected children is 
greatest during infancy, but remains high even in the second, third, and 
fourth years of life.[11] 
Pathophysiology of RSV disease
The viral infection starts in the upper respiratory tract and spreads to the 
lower tract within a few days, resulting in inflammation of the bronchiolar 
epithelium and oedema of the submucosa and adventitia.[26] Plugs of 
sloughed, necrotic epithelium and fibrin and excessive mucus secretion 
add to airway obstruction, causing partial or total obstruction to 
airflow.[27] A ‘ball-valve’ mechanism can result in trapping of air distal 
to obstructed areas, with subsequent absorption, atelectasis, and a 
mismatch of pulmonary ventilation and perfusion that may lead to 
hypoxaemia. Smooth-muscle constriction seems to have a minor role 
in the pathological process, which may explain the limited benefit 
of bronchodilators observed in clinical studies.[26] Although these 
mechanisms are known for RSV bronchiolitis, it is assumed that other 
viruses produce similar pathological conditions.
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